128 related articles for article (PubMed ID: 35842199)
1. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
Lian B; Si L; Chi ZH; Sheng XN; Kong Y; Wang X; Tian H; Li K; Mao LL; Bai X; Tang BX; Yan XQ; Li SM; Zhou L; Dai J; Tang XW; Ran FW; Yao S; Guo J; Cui CL
Ann Oncol; 2022 Oct; 33(10):1061-1070. PubMed ID: 35842199
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
3. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
[TBL] [Abstract][Full Text] [Related]
4. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
5. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
7. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study.
Du Y; Qi Z; Liang X; Dai J; Wei X; Bai X; Mao L; Chi Z; Cui C; Lian B; Tang B; Wang X; Chen Y; Guo J; Si L
Dermatol Pract Concept; 2024 Jan; 14(1):. PubMed ID: 38364395
[TBL] [Abstract][Full Text] [Related]
9. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
10. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.
Lian B; Li Z; Wu N; Li M; Chen X; Zheng H; Gao M; Wang D; Sheng X; Tian H; Si L; Chi Z; Wang X; Lai Y; Sun T; Zhang Q; Kong Y; Long GV; Guo J; Cui C
Ann Oncol; 2024 Feb; 35(2):211-220. PubMed ID: 37956739
[TBL] [Abstract][Full Text] [Related]
12. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
13. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
14. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.
Li J; Wang J; Li D; Wen X; Ding Y; Liu X; Jiang H; Huang F; Zhang X
Dermatol Ther; 2021 Sep; 34(5):e15067. PubMed ID: 34302318
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Eigentler TK; Gutzmer R; Hauschild A; Heinzerling L; Schadendorf D; Nashan D; Hölzle E; Kiecker F; Becker J; Sunderkötter C; Moll I; Richtig E; Pönitzsch I; Pehamberger H; Kaufmann R; Pföhler C; Vogt T; Berking C; Praxmarer M; Garbe C;
Ann Oncol; 2016 Aug; 27(8):1625-32. PubMed ID: 27287206
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Glassee N; Kicinski M; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Giacomo AMD; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Gandini S; Buhrer E; Suciu S; Robert C; Eggermont AMM; Mandala M; Lorigan P; Valpione S
Eur J Cancer; 2024 Apr; 201():113585. PubMed ID: 38402687
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
19. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.
Payne MJ; Argyropoulou K; Lorigan P; McAleer JJ; Farrugia D; Davidson N; Kelly C; Chao D; Marshall E; Han C; Wellman S; Middleton MR
J Clin Oncol; 2014 Jan; 32(3):185-90. PubMed ID: 24344211
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger JM; Darke A; Othus M; Truong TG; Khushalani N; Kendra K; Lewis KD; Faller B; Funchain P; Buchbinder EI; Tarhini AA; Kirkwood JM; Sharon E; Sondak V; Guild SR; Grossmann K; Ribas A; Patel SP
JAMA Oncol; 2023 Feb; 9(2):251-260. PubMed ID: 36416836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
